PL377376A1 - Sposoby ochrony przed uszkodzeniem przez promieniowanie z użyciem Ó-tymozyny - Google Patents

Sposoby ochrony przed uszkodzeniem przez promieniowanie z użyciem Ó-tymozyny

Info

Publication number
PL377376A1
PL377376A1 PL377376A PL37737603A PL377376A1 PL 377376 A1 PL377376 A1 PL 377376A1 PL 377376 A PL377376 A PL 377376A PL 37737603 A PL37737603 A PL 37737603A PL 377376 A1 PL377376 A1 PL 377376A1
Authority
PL
Poland
Prior art keywords
methods
protecting against
radiation damage
against radiation
alpha thymosin
Prior art date
Application number
PL377376A
Other languages
English (en)
Inventor
Alfred R. Rudolph
Cynthia W. Tuthill
Original Assignee
Sciclone Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals, Inc. filed Critical Sciclone Pharmaceuticals, Inc.
Publication of PL377376A1 publication Critical patent/PL377376A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL377376A 2002-11-25 2003-11-25 Sposoby ochrony przed uszkodzeniem przez promieniowanie z użyciem Ó-tymozyny PL377376A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42874602P 2002-11-25 2002-11-25

Publications (1)

Publication Number Publication Date
PL377376A1 true PL377376A1 (pl) 2006-02-06

Family

ID=32393452

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377376A PL377376A1 (pl) 2002-11-25 2003-11-25 Sposoby ochrony przed uszkodzeniem przez promieniowanie z użyciem Ó-tymozyny

Country Status (16)

Country Link
US (1) US7897567B2 (pl)
EP (1) EP1570269B1 (pl)
JP (1) JP2006507349A (pl)
KR (1) KR20050086819A (pl)
CN (1) CN100501400C (pl)
AT (1) ATE511852T1 (pl)
AU (1) AU2003295838B2 (pl)
BR (2) BRPI0316646A8 (pl)
CA (1) CA2506893A1 (pl)
EA (1) EA008059B1 (pl)
MX (1) MXPA05005538A (pl)
NO (1) NO330217B1 (pl)
NZ (1) NZ540847A (pl)
PL (1) PL377376A1 (pl)
UA (1) UA81932C2 (pl)
WO (1) WO2004048971A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
CN1822850A (zh) * 2003-07-18 2006-08-23 雷根内克斯生物制药有限公司 由放射线照射引起的损伤的治疗或预防
CN101443080B (zh) * 2006-03-07 2015-01-14 比奥滕普特公司 肽在控制辐射损伤中的用途
CN103458681A (zh) * 2011-02-09 2013-12-18 赛生制药有限公司 用于预防感染、降低感染的严重性、及治疗感染的胸腺素α肽
US20130296223A1 (en) * 2012-03-30 2013-11-07 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for the treatment of sepsis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1195980A (en) 1966-08-24 1970-06-24 Univ Yeshiva Hormone-Like Preparations Derived from Thymus Gland and Methods of Producing the Same.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4079127A (en) 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en) 1978-01-23 1979-04-10 Hoffmann-La Roche Inc. Synthesis of thymosin α1
DE2919592A1 (de) 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
CN1094310A (zh) 1992-12-15 1994-11-02 托马斯·C·梅里根 人体免疫缺陷性病毒感染用组合式化学疗法
TW252045B (pl) * 1993-10-07 1995-07-21 Allan L Goldstein
EP0730470B1 (en) 1993-11-10 2002-03-27 Enzon, Inc. Improved interferon polymer conjugates
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6197751B1 (en) 1997-11-10 2001-03-06 The United States Of America As Represented By The Department Of Health And Human Services Thymosin α1 promotes tissue repair, angiogenesis and cell migration
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
CN1303713A (zh) 2000-01-07 2001-07-18 广州暨南大学医药生物技术研究开发中心 预防和治疗辐射损伤的保健组合物
US6462017B1 (en) * 2000-05-01 2002-10-08 Sciclone Pharmaceuticals, Inc. Method of reducing side effects of chemotherapy in cancer patients
ATE537845T1 (de) 2000-10-31 2012-01-15 Pr Pharmaceuticals Inc Verfahren zur herstellung von formulierungen zur verbesserten abgabe von bioaktiven molekülen
UA80957C2 (en) 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
UA78726C2 (en) 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment

Also Published As

Publication number Publication date
NO330217B1 (no) 2011-03-07
AU2003295838B2 (en) 2008-05-22
US7897567B2 (en) 2011-03-01
ATE511852T1 (de) 2011-06-15
JP2006507349A (ja) 2006-03-02
CN100501400C (zh) 2009-06-17
MXPA05005538A (es) 2005-08-16
KR20050086819A (ko) 2005-08-30
EA200500773A1 (ru) 2005-12-29
CN1717587A (zh) 2006-01-04
AU2003295838A1 (en) 2004-06-18
BRPI0316646A8 (pt) 2018-04-24
WO2004048971A1 (en) 2004-06-10
US20060166877A1 (en) 2006-07-27
EP1570269A4 (en) 2008-09-10
CA2506893A1 (en) 2004-06-10
NO20052943L (no) 2005-08-09
NO20052943D0 (no) 2005-06-16
EP1570269B1 (en) 2011-06-08
BR0316646A (pt) 2005-10-11
EP1570269A1 (en) 2005-09-07
EA008059B1 (ru) 2007-02-27
UA81932C2 (uk) 2008-02-25
NZ540847A (en) 2006-07-28

Similar Documents

Publication Publication Date Title
EP1575528A4 (en) TREATMENT PROTECTIVE CYTOKINS FOR THE PROTECTION, RECOVERY AND STRENGTHENING OF RESPECTIVE CELLS, TISSUE AND ORGANS
MY133569A (en) Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
AU2003213768A1 (en) Use of benzimidazole analogs in the treatment of cell proliferation
NZ506214A (en) Therapy for alpha-galactosidase A deficiency
TW200505434A (en) Therapeutic treatment
DK1278987T3 (da) Gasflaske med beskyttelseskapper til anvendelse indenfor det medicinske område
IL163666A0 (en) Active agent delivery systems and methods for protecting and administering active agents
TW200512007A (en) Cosmetic compositions containing fullerene clusters
PL375900A1 (pl) Postacie dawkowania zawierające inhibitor pompy protonowej, NSAID oraz bufor
NO20052943L (no) Fremgangsmate for beskyttelse mot stralingsskade ved hjelp av alfa-tymosin
GB2396108B (en) Treatment of pain
EP0716609A4 (en) METHODS AND COMPOSITIONS FOR STIMULATING AND INHIBITING TGF - g (b) ACTIVITY
DK85193D0 (da) Suppression of inhibitors
EP1155677A3 (en) Methods and compositions for inhibiting free radical polymerization in skin and hair
BR0114604A (pt) Tratamento de c‰nceres
EP1613340A4 (en) TREATMENT OF ASPERGILLUS INFECTIONS WITH THYMOSINE ALPHA 1
UA83628C2 (ru) Способ защиты эндотелиальных и эпителиальных клеток во время трансплантации алогенных стволовых клеток
MY118982A (en) Method of reducing tissue damage associated with ischemia
DE60130253D1 (de) Zusammensetzungen zur verhinderung der adhäsion
ES2193285T3 (es) Inhibidor de oxido nitrico (no)-sintasa para prevenir la diabetes de tipo ii.
EP1146866A4 (en) METHOD OF TREATMENT OF ACNEEPATIENTS BY ADMINISTERING CYCLIC GMP PDE INHIBITORS
RU97108756A (ru) Средство для защиты организма от воздействия повреждающих факторов внешней среды и способ профилактики и лечения организма от воздействия ионизирующего излучения
Wu The Old Layer of the Personal and Demonstrative Pronoun System and its Development in the Hunan Dialects
PL358046A1 (pl) Sposób aktywnego zabezpieczania i reagowania na zagrożenie powodzią
HN2003000193A (es) Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age.

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)